OnKure Therapeutics (OKUR) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company developing precision medicines targeting biologically validated drivers of cancers and vascular anomalies underserved by current therapies.

• Utilizes a structure-based drug design platform to create small molecule drugs that selectively target mutated proteins, aiming for improved efficacy and safety.

• Focuses on sparing wild-type enzymes to reduce toxicity and enable precise patient selection for higher clinical success rates.

• Incorporated in Delaware, underwent a merger and rebranding in October 2024, and now trades on Nasdaq under the symbol "OKUR."

Financial performance and metrics

• Raised approximately $150 million in a private placement on March 31, 2026, selling 26,713,638 shares at $4.15 per share and pre-funded warrants for 9,430,957 shares at $4.1499 per share.

• Audit report notes recurring losses and negative cash flows from operations, raising substantial doubt about the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; only receives cash upon exercise of pre-funded warrants.

• Proceeds from warrant exercises, if any, will be used for general corporate purposes.